Anlon Healthcare IPO Subscription Status
Anlon Healthcare IPO subscribed over 7.12x on its Last day till 05.00 PM on 29th August 2025.
- Anlon Healthcare IPO subscription QIB investors’ portion is 1.07x times, while NII subscribed 10.61x times, and RII investors subscribed 47.26x times.
- The company has received bids for 9,47,08,360 shares against 1,33,00,000 shares on offer on the Last day.
- Anlon Healthcare IPO subscribed over 3.30x times on day 2.
- Anlon Healthcare IPO subscribed over 1.69x times on day 1.
About the Anlon Healthcare IPO
Anlon Healthcare Limited, founded in 2013, is one of the growing chemical manufacturing companies engaged in the manufacturing of 2 things: 1. high-purity advanced pharmaceutical intermediates used as raw materials for making active pharmaceutical ingredients (APIs). 2. APIs are used in medicines like tablets, capsules, ointments, syrups, as well as in nutraceuticals, personal care, and animal health products. Its portfolio consists of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), nutraceutical APIs, and ingredients for personal care and veterinary use.
Moreover, among a few other companies, Anlon Healthcare is an Indian maker of loxoprofen sodium dihydrate, which is an API widely useful to treat severe pain like arthritis, back pain, frozen shoulder, tooth pain, or post-surgery recovery. The company had 105 employees (excluding trainees) and 8 contract workers as of January 31, 2025. As of the date of filing the DRHP, the company has 65 commercial products, 28 at the pilot stage, and 49 in laboratory testing.
Anlon Healthcare IPO Company Financial Report
The company reported revenue of ₹66.69 crores in 2024 against ₹113.12 crores in 2023. The company reported a profit of ₹9.66 crores in 2024 against a profit of ₹5.82 crores in 2023.
Anlon Healthcare IPO GMP
Anlon Healthcare IPO GMP was ₹6 as of Friday, 29th August. That indicates the IPO is trading at ₹97 with a ₹6 premium in the grey market against the issue price of ₹91.
